Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veterans in key operational and advisory roles. Dave Domzalski has been appointed President of Foamix Pharmaceuticals Inc., the U.S. subsidiary of Foamix Ltd., Dr. Herman Ellman has been appointed Vice President of Clinical Affairs and Alvin Howard has been appointed Vice President of Regulatory Affairs. Two new external advisors, Carl Reichel and Anthony Bruno, will both serve as Strategic Advisors to management. - See more at: http://www.globenewswire.com/news-release/2014/06/11/643443/10085379/en/Foamix-Establishes-U-S-Subsidiary-and-Strengthens-Executive-Management-With-Appointment-of-Senior-U-S-Leadership-Team.html#sthash.hiMVBCd3.dpuf